Cancer Vaccine Developer Files Ch. 7 After Trials Fall Short
A Denmark-based biotechnology firm filed for Chapter 7 liquidation Tuesday in Delaware with more than $10 million in debt after its prospective cancer vaccine failed to measure up under testing and...To view the full article, register now.
Already a subscriber? Click here to view full article